Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Inflammation Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1494901

JAK inhibitors: an evidence-based choice of the most appropriate molecule

Provisionally accepted
Luca Antonioli Luca Antonioli 1*Alessandro Armuzzi Alessandro Armuzzi 2Massimo C. Fantini Massimo C. Fantini 3Matteo Fornai Matteo Fornai 1
  • 1 University of Pisa, Pisa, Tuscany, Italy
  • 2 Humanitas Research Hospital, Rozzano, Lombardy, Italy
  • 3 University of Cagliari, Cagliari, Sardinia, Italy

The final, formatted version of the article will be published soon.

    Janus kinase inhibitors (JAKis) represent a fundamental therapeutic tool for the treatment of patients with immune-mediated inflammatory diseases. Although JAKis are often considered a homogeneous class of drugs whose members are thought to be largely interchangeable, there are significant differences in their efficacy and safety profiles. This narrative review analyzes the pharmacokinetic and pharmacodynamic differences among JAKIs, highlighting their clinical relevance based on the most recent available evidence. The article aims to provide rheumatologists, gastroenterologists and dermatologists with practical guidance for choosing the most appropriate JAKi for each patient, given the lack of evidence-based recommendations on this topic, to improve clinical outcomes. Due to its preferential action on JAK1, intestinal metabolization and proven absence of impact on male fertility, filgotinib may be characterized by an improved benefit/risk ratio compared with other less selective JAKis.

    Keywords: JAK inhibitors, pharmacokinetic, Pharmacodynamic, efficacy, Safety

    Received: 11 Sep 2024; Accepted: 18 Oct 2024.

    Copyright: © 2024 Antonioli, Armuzzi, Fantini and Fornai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Luca Antonioli, University of Pisa, Pisa, 56126, Tuscany, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.